Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
Adenocarcinoma, Clear Cell
Antineoplastic Agents, Phytogenic
Neoplasm Recurrence, Local
(1) Paclitaxel administered as a 1-hour infusion is well tolerated; (2) this schedule of administration does not result in cumulative myelosuppression; and (3) this schedule of administration results in dose-intensive paclitaxel delivery with a favorable toxicity profile.